After numerous rejections, Discovery responds again to US FDA on Surfaxin
This article was originally published in Scrip
Executive Summary
Discovery Labs submitted its response to the US FDA for the firm's embattled humanised surfactant Surfaxin (lucinactant), which received four rejections from the agency, with the most recent in April 2009 (scripintelligence, 21 April 2009).